Adaptive Biotechnologies understands that each patient's situation is unique. We are committed to providing guidance and support during each step of the insurance process.
That's why we offer the Adaptive Assist program: to help facilitate access to clonoSEQ testing services for patients who could benefit from the clinical insights provided by next-generation measurable residual (MRD) testing.
To visit the Website CLICK HERE
MSHO will profile a different Corporate Sponsor Assistance Program in each Bulletin. To view more Patient Assistance Programs, click here.